

## Q1 Report 2019


Mattias Perjos, President and CEO Lars Sandström, CFO

April 23, 2019



## Key takeaways – performance Q1 2019

- Sales growth continues
- Positive growth outlook
- Gross Margin improved sequentially
- Improved adj EBITA Margin Y-o-Y
- Positive development on Working Capital and stable Cash Flow






### Key takeaways – events Q1 2019

- Restructuring activities to reduce expenses and improve productivity
  - Restructuring cost of SEK 108 M in the quarter
  - Margin contribution is expected to start to show on P&L from H2 2019
- No new material information on Brazil, Mesh litigations and FDA Warning Letters
- FDA approval: Servo-u and Servo-n software, supporting continued growth in Critical Care



### **Organic growth continues**


Order Intake and Net Sales growth in all regions and business areas



GETINGE 🛠


## **Contribution in Order Intake Q1 2019**

Strong organic growth in all Business Areas



## **Contribution in Net Sales Q1 2019**


Organic growth in all business areas – capital goods growing 10 pp faster than consumables



Getinge Q1 Report 2019 April 23, 2019 Page 6

## **Gross Margin development Q1 2019**


Margin supported by volume growth but negatively impacted by currency effects and product mix



# Financial development




### Adjusted EBITA Bridge Q1 2018 – Q1 2019



MSEK






## **Control on OPEX**

FTE's and OPEX in relation to Net Sales continue to move in a positive direction



#### **Decreasing number of FTE's**



#### Decreasing adj OPEX in relation to Net Sales

Getinge Q1 Report 2019 April 23, 2019 Page 11

## Stable cash flow development

- Cash flow positively impacted by increasing profit
- Working Capital is stable vs. previous year despite strong growth in net sales
- Net debt is negatively impacted mainly by currency effects and IFRS 16-effects
- Leverage (Net debt/adj EBITDA R12M) is in line with Q4 2018 when adjusted for IFRS 16-effects

SEK M	Jan-Mar 2019	Jan-Mar 2018	Jan-Dec 2018
Cash flow before changes in working capital	356	272	2,641
Changes in working capital	31	26	-138
Net investments in non-current assets	-248	-299	-1,335
Cash flow after net investments	139	-1	1,168
Whereof IFRS 16-effect	86	-	-
Net interest-bearing debt at end of the period	13,953	13,079	12,591
In relation to adj EBITDA R12, multiple	3.4	3.2	3.2
Net interest-bearing debt at end of the period, excl IFRS 16 effect	12,947		
In relation to adj EBITDA R12, excl IFRS 16 effect, multiple	3.2		

### **Stable cash flow development**

Working Capital is declining in days and in absolute terms



Working Capital is decreasing despite strong sales growth

Working Capital, as defined on this page, is including accounts receivables, accounts payables and inventory - adjusted for currency

Getinge Q1 Report 2019 April 23, 2019 Page 13

## Outlook



## Outlook 2019



**Organic Net Sales Growth** 



# Summary





- Sales growth continues
- Positive growth outlook
- Gross Margin improved sequentially
- Improved adj EBITA Margin Y-o-Y
- Positive development on Working Capital and stable Cash Flow
- Restructuring activities expected to start support margins from H2 2019







# Thank you



## **Forward looking information**

This document contains forward-looking information based on the current expectations of the Getinge's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.





### PASSION FOR LIFE